Latest & greatest articles for olmesartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on olmesartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on olmesartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for olmesartan

1. Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis. (Abstract)

Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis. The comparison of antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension has been investigated in several studies. The results were not consistent. We performed this meta-analysis determining the antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension.Pubmed, Web of Science, and Cochrane Central were (...) searched for all published randomized studies comparing the antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension.The antihypertensive effects were assessed in 1402 patients included in five trials. The reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan (weighted mean differences (WMD) - 2.15 (95% confidence interval (CI), - 3.78, - 0.53) mm Hg, p < 0.01). There was no significant difference in reduction of office

2020 Irish journal of medical science

2. Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. (Full text)

Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. The efficacy and safety of olmesartan medoxomil (OM) vs active control (AC) monotherapy among elderly patients aged 60-79 years (N = 4487) was evaluated by meta-analysis (25 studies). In all patients, change from baseline to end point in blood pressure (BP) was significantly greater with OM vs AC (-19.5/-11.9 vs -16.8/-10.7 mm Hg). Greater proportions of OM- vs AC-treated patients

2019 Journal of clinical hypertension (Greenwich, Conn.) PubMed abstract

3. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension (Full text)

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ). One analysis pooled 1,610 patients from two 6

2018 EvidenceUpdates PubMed abstract

4. Olmesartan

Olmesartan Top results for olmesartan - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for olmesartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

5. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. (Full text)

Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. Antihypertensive monotherapy is often insufficient to control blood pressure (BP). Several recent guidelines advocate for initial combination drug therapy in many patients. This meta-analysis of seven randomized, double-blind studies (N = 5888) evaluated 8 weeks of olmesartan medoxomil (OM)-based single-pill dual-combination therapy (OM+amlodipine/azelnidipine

2017 Journal of clinical hypertension (Greenwich, Conn.) PubMed abstract

6. Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data. (Abstract)

Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data. Results from two long-term studies (ROADMAP and ORIENT) indicated a numerical imbalance in the number of cardiovascular deaths between the olmesartan medoxomil (OM) and placebo groups.Our objective was to conduct an individual patient data meta-analysis to provide more complete information regarding OM-associated cardiovascular risks and/or benefits.We created an integrated

2016 American journal of cardiovascular drugs : drugs, devices, and other interventions

7. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. (Abstract)

A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. The objective of the present study was to systematically review the clinical and economic outcomes of olmesartan as monotherapy or in combination with other antihypertensive agents in the treatment of hypertension. A literature search was performed using PubMed and the Cochrane library until December 2015, with no limit on publication date. Eligible studies were selected (...) using predetermined inclusion and exclusion criteria, limiting articles to those published in the English language. Background information of the study, participants' characteristics and study outcomes were collected. Meta-analysis of data was not performed. Fifty-five studies were included, of which fifty investigated the clinical efficacy of olmesartan and five the cost-effectiveness of olmesartan. In general results from clinical trials evaluating the efficacy of olmesartan as monotherapy

2016 International journal of cardiology

8. Hypertension: avoid olmesartan pending its withdrawal

Hypertension: avoid olmesartan pending its withdrawal Prescrire IN ENGLISH - Spotlight ''Hypertension: avoid olmesartan pending its withdrawal'', 1 May 2016 {1} {1} {1} | | > > > Hypertension: avoid olmesartan pending its withdrawal Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Hypertension: avoid olmesartan pending its withdrawal Olmesartan (...) exposes patients to increased, and sometimes severe, gastrointestinal adverse effects. It is in the best interest of patients not to use it. Olmesartan, commercialised for hypertension, is no more effective than the other sartans or than ACEs (angiotensin-converting enzyme inhibitors) against the cardiovascular complications of hypertension. Since mid-2012, excessive, sometimes severe, gastrointestinal adverse effects (enteropathies) with diarrhoea, sometimes intense abdominal pains, weight loss, etc

2016 Prescrire

9. Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block (Full text)

Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block 28868435 2018 11 13 2341-4545 23 2 2016 Mar-Apr GE Portuguese journal of gastroenterology GE Port J Gastroenterol Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block. 61-65 10.1016/j.jpge.2016.02.005 Hujoel Isabel A IA Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. Rubio-Tapia Alberto A Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

2016 GE Portuguese journal of gastroenterology PubMed abstract

10. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. (Abstract)

Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Sprue-like enteropathy associated with the angiotensin II receptor blocker (ARB) olmesartan was first described in 2012, and a number of cases have since been reported. This syndrome is characterized by severe diarrhea and sprue-like histopathologic findings in the intestine, often with increased subepithelial collagen. The incidence of this adverse drug reaction is not entirely clear, although (...) it is thought to be rare. It is also not well established if other ARBs cause such a syndrome, although case reports suggest they can. The histopathologic features of olmesartan-related injury have only been described in a limited number of cases, and there are no guidelines regarding the histopathologic distinction of olmesartan-associated enteropathy from other causes of sprue (eg, celiac disease, tropical sprue). Herein, we review the histopathologic changes and clinical observations described in recent

2016 Human pathology

11. Olmesartan-Induced Sprue Like Enteropathy (Full text)

Olmesartan-Induced Sprue Like Enteropathy Chronic diarrhoea is a common clinical problem in gastroenterology practice and often it is difficult to diagnose the cause. Villous atrophy is not specific and the rarer possibility of drug-induced enteritis should always be considered. Olmesartan has recently been described as a cause of drug-induced enteropathy characterized by chronic diarrhoea and varying degrees of duodenal mucosa atrophy resembling celiac disease. We describe two cases of sprue (...) -like enteropathy in patients treated with olmesartan for arterial hypertension several years before the onset of symptoms. Patients presented severe diarrhoea and significant weight loss, and both had histological evidence of intestinal villous atrophy. The clinical signs completely resolved after drug withdrawal. Olmesartan-induced enteropathy is a new clinical entity that must be included in the differential diagnosis of villous atrophy with negative celiac serology. The clinical and histological

2016 GE Portuguese journal of gastroenterology PubMed abstract

12. Enteropathy Associated with Olmesartan (Full text)

Enteropathy Associated with Olmesartan The recognition of an enteropathy caused by olmesartan is recent. It was first described in 2012 by the Mayo Clinic, which presented 22 clinical cases. Olmesartan is a highly prescribed drug and the differential diagnosis of a sprue-like enteropathy is very wide, so it is important to be aware of this pathology. We report a case of a 67-years-old man, with arterial hypertension under treatment with olmesartan, with a 4-months history of diarrhea and weight (...) lost. He was admitted three times in our Department during this period of time. An initial diagnosis was made of lymphocytic colitis but he did not respond to treatment with corticosteroids. There was a high suspicion of celiac disease, so the patient started a gluten-free diet but still there were no symptomatic changes. The patient underwent several blood and imaging tests which were negative. Due to the suspicion of an enteropathy caused by drugs, olmesartan was stopped and the patient showed

2015 GE Portuguese journal of gastroenterology PubMed abstract

13. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. (Abstract)

Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been shown to be effective and well tolerated in hypertensive patients. Olmesartan is the seventh angiotensin receptor blocker licensed by the US Food and Drug Administration. The aim of this meta-analysis was to determine the efficacy and tolerability of olmesartan medoxomil in comparison with other (...) ARBs.Reports of randomized controlled trials (RCTs) of olmesartan versus other ARBs were identified through a systematic search of PubMed (up to July 2010), EMBASE (1980 to July 2010), SinoMed (up to July 2010), and the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 7, 2010).Pertinent studies were selected through extensive searches of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and SinoMed. Two of the authors abstracted data from the identified studies

2015 American journal of cardiovascular drugs : drugs, devices, and other interventions

14. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study (Abstract)

Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study Severe sprue-like enteropathy associated with olmesartan has been reported, but there has been no demonstration of an increased risk by epidemiological studies.To assess, in a nationwide patient cohort, the risk of hospitalisation for intestinal malabsorption associated with olmesartan compared with other angiotensin receptor blockers (ARB) and ACE inhibitors (ACEIs).From the French (...) , the adjusted rate ratio of hospitalisation with a discharge diagnosis of intestinal malabsorption was 2.49 (95% CI 1.73 to 3.57, p<0.0001) in olmesartan users. This adjusted rate ratio was 0.76 (95% CI 0.39 to 1.49, p=0.43) for treatment duration shorter than 1 year, 3.66 (95% CI 1.84 to 7.29, p<0.001) between 1 and 2 years and 10.65 (95% CI 5.05 to 22.46, p<0.0001) beyond 2 years of exposure. Median length of hospital stay for intestinal malabsorption was longer in the olmesartan group than in the other

2015 EvidenceUpdates

15. Systematic review: Sprue-like enteropathy associated with olmesartan. (Abstract)

Systematic review: Sprue-like enteropathy associated with olmesartan. The onset of a sprue-like enteropathy in association with olmesartan therapy has been recently reported.To perform a systematic review of the literature and describe three additional cases of olmesartan-associated enteropathy.Electronic and manual bibliographic searches were performed to identify original reports in which subjects who were undertaking olmesartan developed a sprue-like enteropathy. Because of the scarcity (...) disease was always negative. Variable degrees of duodenal villous atrophy were present in 98% of patients, while increased intra-epithelial lymphocytes were documented in only 65% of cases. After discontinuation of olmesartan, all reported patients achieved resolution of signs and symptoms.Although the available evidence is limited, the olmesartan-associated sprue-like enteropathy may be considered as a distinct clinical entity, and should be included in the differential diagnosis when serological

2014 Alimentary Pharmacology & Therapeutics

16. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern? (Abstract)

Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern? 21840109 2012 08 21 2012 12 31 1885-5857 65 4 2012 Apr Revista espanola de cardiologia (English ed.) Rev Esp Cardiol (Engl Ed) Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern? 378-80 10.1016/j.recesp.2011.05.024 Consuegra-Sánchez Luciano L Sanchis Juan J (...) Núñez Julio J Cascón José Domingo JD Villegas Manuel M Picó Francisco F eng Letter Meta-Analysis 2011 08 12 Spain Rev Esp Cardiol (Engl Ed) 101587954 1885-5857 0 Angiotensin II Type 1 Receptor Blockers 0 Imidazoles 0 Tetrazoles 8W1IQP3U10 olmesartan IM Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):678-9; author reply 679-80 22608016 Aged Albuminuria drug therapy etiology Angiotensin II Type 1 Receptor Blockers adverse effects therapeutic use Diabetes Mellitus, Type 2 complications mortality Diabetic

2012 Revista española de cardiología (English ed.)

17. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis

Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

18. Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens

Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Belsey JD Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim of the study was to compare mean costs per patient of target-driven hypertension treatment using olmesartan with the same approach using candesartan in patients with previously untreated moderate hypertension in the UK. The authors

2011 NHS Economic Evaluation Database.

19. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. (Full text)

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 patients with type 2 diabetes to receive olmesartan (...) (at a dose of 40 mg once daily) or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria. The times to the onset of renal and cardiovascular events were analyzed as secondary end points.The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan

2011 NEJM Controlled trial quality: predicted high PubMed abstract

20. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis (Full text)

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis.Prior intravascular ultrasound (IVUS) trial results suggest slowing of coronary atheroma progression with some medicines but have not shown convincing evidence of regression with angiotension-II (...) receptor blocking agents.A prospective, randomized, multicenter trial-OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound)-was performed in 247 stable angina pectoris patients with native coronary artery disease. When these patients underwent percutaneous coronary intervention for culprit lesions, IVUS was performed in their nonculprit vessels (without angiographically documented coronary stenosis [<50%]). Patients were randomly assigned

2010 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract